Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Am J Reprod Immunol. 2021 Mar;85(3):e13341. doi: 10.1111/aji.13341. Epub 2020 Sep 18.
The association between subclinical hypothyroidism (SCH) and recurrent pregnancy loss (RPL) remains unclear. We evaluated whether SCH affects subsequent live births and whether levothyroxine is effective in improving the live birth rate in patients with RPL.
This observational cohort study included 1418 pregnancies of 1014 patients with a history of 2 or more pregnancy losses, who were euthyroid or had hypothyroidism, and had at least one subsequent pregnancy outcome. Some patients with SCH, as defined as a TSH >2.5 mIU/L, were treated with levothyroxine, and these comprised the levothyroxine group. The prevalence of SCH, subsequent live birth rates per patient and per pregnancy were compared among patients with SCH treated with and without levothyroxine and patients with euthyroid.
The prevalence of SCH was 14.4%. Subsequent live birth rates were 75.0% for the levothyroxine group, 68.6% for the untreated SCH group, and 70.1% for the euthyroid group. After excluding miscarriages with abnormal karyotypes, live birth rates were 89.2%, 90.0%, and 91.1%. The adjusted odds ratio (95%CI) was 0.95 (0.23-3.83) after controlling covariables when comparing SCH patients with and without treatment. The live birth rates per pregnancy were 93.1%, 85.7%, and 90.9%, respectively. The adjusted OR was 0.95 (0.23-3.83).
Levothyroxine has no effect on improving the live birth rate in patients with RPL associated with SCH. Treatment in patients with RPL and SCH raised TSH levels (2.5-10mIU/L) might not be beneficial in improving the live birth rate.
亚临床甲状腺功能减退症(SCH)与复发性妊娠丢失(RPL)之间的关联尚不清楚。我们评估了 SCH 是否影响随后的活产,以及左甲状腺素是否能有效提高 RPL 患者的活产率。
这项观察性队列研究纳入了 1014 例有 2 次或 2 次以上妊娠丢失史的患者的 1418 次妊娠,这些患者甲状腺功能正常或患有甲状腺功能减退症,且至少有一次后续妊娠结局。一些 SCH 患者(定义为 TSH>2.5 mIU/L)接受了左甲状腺素治疗,这些患者构成了左甲状腺素组。比较了 SCH 患者在接受和未接受左甲状腺素治疗以及甲状腺功能正常的患者中 SCH 的患病率、每位患者和每次妊娠的后续活产率。
SCH 的患病率为 14.4%。左甲状腺素组的后续活产率为 75.0%,未治疗的 SCH 组为 68.6%,甲状腺功能正常组为 70.1%。排除异常核型流产后,活产率分别为 89.2%、90.0%和 91.1%。在控制了协变量后,SCH 患者无论是否接受治疗,其调整后的优势比(95%CI)分别为 0.95(0.23-3.83)。每个妊娠的活产率分别为 93.1%、85.7%和 90.9%,调整后的 OR 分别为 0.95(0.23-3.83)。
左甲状腺素对改善与 SCH 相关的 RPL 患者的活产率没有影响。治疗 RPL 和 SCH 患者的 TSH 水平(2.5-10 mIU/L)可能无益于提高活产率。